In This Section
Dr. Pamela Weiss is an experienced academic pediatric rheumatologist with advanced training in clinical epidemiology and a focus on early diagnosis, accurate phenotyping, and targeted treatment of children with juvenile arthritis. Her research consists of a mixture of prospective interventional, prospective observational and retrospective large database-driven work.
Dr. Weiss’s research focuses on early diagnosis, accurate phenotyping and targeted treatment of children with spondyloarthritis (SpA).
Juvenile SpA is heterogeneous group of disorders characterized by varying degrees of arthritis of the peripheral skeleton (knees, ankles, etc), enthesitis (inflammation of the tendon insertions), symptomatic eye inflammation, gut inflammation, and axial arthritis (sacroiliac joints +/- spine joints) accompanied by overlapping genetic susceptibility. Dr. Weiss has directed efforts to optimize evaluation of early disease phenotype, including the of the imaging of axial arthritis. Her prior work includes publications demonstrating the limited utility of plain radiographs in the evaluation of early axial disease as well as the limited usefulness of intravenous contrast when evaluating for sacroiliac joint inflammation on MRI. She has also demonstrated variation in MRI evaluation and interpretation of the sacroiliac joint across academic institutions and underscored the need for additional training of rheumatologists and radiologists regarding the normal appearance of the sacroiliac joint. She has collaborated with international colleagues and imaging experts to validate clinical disease activity scores and imaging tools to assess change over time.
Since there is no standardized approach to the initial treatment of spondyloarthritis, understanding the comparative effectiveness and efficacy of the diverse therapeutic options and standardization of care will result in better health outcomes. Dr. Weiss has worked with existing clinical data to compare the effectiveness of established treatments and is also involved in clinical trials to evaluate the efficacy of newer targeted therapies. For those patients who have achieved sustained remission, Dr. Weiss is also investigating the ability to safely taper or stop medications. Lastly, Dr. Weiss has collaborated with patient and parent stakeholders to evaluate patient reported outcomes in spondyloarthritis.
Education and Training
BA, Princeton University (Molecular Biology), 1998
MD, Albert Einstein College of Medicine, 2002
MSCE, University of Pennsylvania (Clinical Epidemiology and Biostatistics), 2009
Titles and Academic Titles
Clinical Research Director, Division of Rheumatology
Chair, Clinical Trials Research Affinity Group
Associate Professor of Pediatrics
Associate Co-director for Clinical Trials, Center for Pediatric Clinical Effectiveness
American Academy of Pediatrics, 2002-
American College of Rheumatology, 2005-
Arthritis Foundation, 2005-
Childhood Arthritis and Rheumatology Research Alliance, 2005-
Spondyloarthritis Research & Treatment Network, 2012-
National Institute of Child Health and Human Development, 2012-
Pediatric Rheumatology Collaborative Study Group, 2018-
American Women's Medical Association Janet M. Glasgow Achievement Citation, Albert Einstein Medical College of Medicine, 2002
American College of Rheumatology/Research Education Fund Medical and Pediatric Resident Research Award, 2008
Professional Educator Award, Arthritis Foundation, 2012
Spondylitis Association of America-Jane Bruckel Young Investigator Award, 2014
American College of Rheumatology Henry Kunkel Young Investigator Award, 2020